Drugs metabolically eliminated by several enzymes are less vulnerable to variable compound exposure in patients due to drug-drug interactions (DDI) or if a polymorphic enzyme is involved in their elimination. Therefore, it is vital in drug discovery to accurately and efficiently estimate and optimize the metabolic elimination profile.
Introduction
A drug being eliminated by multiple clearance pathways has a lower risk of large variations in drug exposure in the patient population, in comparison with a drug metabolically eliminated by a single enzyme. One source of variability is drug-drug interactions (DDI) as co-administered drugs may inhibit or facilitate the metabolic clearance, which may result in higher or lower drug concentration, respectively, in patients than intended and an increased risk of adverse drug reactions (Lynch and Price, 2007) or lack of efficacy. Drugs cleared mainly via one enzyme are highly sensitive to inhibition or induction of this only clearance route. Today, polypharmacy is more a norm than an exception, especially in the area of cardiovascular and metabolic diseases in an ageing population where patients are commonly prescribed more than 10 medications (Rifkin et al., 2010) , increasing the potential of undesirable DDI. Another source of variability during drug exposure is the dependency of clearance on a polymorphic enzyme, which may result in large variations in exposure due to the different phenotypes in the patient population (Dayer et al., 1985) . The risk of adverse drug reactions is higher in poor metabolizers (PM) if the safety margins are narrow (Ingelman-Sundberg, 2004) . In ultra-rapid metabolizers (UM), there is a risk of exposure below therapeutic levels and as a consequence a limited pharmacological effect. Prodrugs dependent on metabolism by a polymorphic enzyme for conversion to the active drug carry a risk of adverse drug reactions in UM due to elevated exposure of the active drug and lack of effect in PM due to low exposure of the active drug.
Cytochrome P450 (CYP, P450) (Harding et al., 2018 ) is involved in the metabolic clearance of more than 90% of all drugs (Rendic and Guengerich, 2015) , which makes P450 enzymes a major contributor to DDI, as described above. Therefore, quantifying the fraction of total hepatic clearance due to a specific P450 isoform (fm CYP ) of new chemical entities (NCE) in drug discovery is of critical importance and there are several in vitro methods available (Bohnert et al., 2016) . One common method is to use a panel of human recombinant P450s (hrP450). To predict fm CYP values, intersystem extrapolation factors (ISEF) combined with abundance of the individual P450s in the liver are used to scale intrinsic clearance (CL int ) values in hrP450s to CL int in human liver microsomes (HLM) (Proctor et al., 2004) . An alternative method is to incubate NCE with human liver microsomes or hepatocytes with and without selective P450 inhibitors and determine CL int both in the presence and absence of inhibitor (Rodrigues and Wong, 1997; Li et al., 1999; 2007; Lu et al., 2008; Desbans et al., 2014) .
CYP3A and the polymorphic CYP2D6 enzyme metabolize more than 50% of clinically used drugs (Zanger and Schwab, 2013; Rendic and Guengerich, 2015) . For this reason, we selected a representative set of substrates metabolized to different extents by these two enzymes, for which robust in vivo pharmacokinetic (PK) data from DDI studies with ketoconazole as well as studies on extensive (EM) and poor (PM) metabolizers for CYP2D6 in humans are available ( Figure 1 ). The aim of the present study was to assess the accuracy of a predicted increase in drug exposure when coadministered with the potent CYP3A inhibitor ketoconazole and in CYP2D6 PM versus EM. Two in vitro models, primary human hepatocytes and recombinant P450 enzymes were applied, and the predicted results from in silico tools were compared to clinical in vivo data demonstrating variation in exposure due to CYP3A victim DDI or CYP2D6 polymorphism.
Figure 1
Names, abbreviations and chemical structures of compounds used for assessment of AUC-fold increases by co-administration of ketoconazole and in CYP2D6 PMs.
Methods

Group size, randomization and blinding of experimental data
The assays evaluated, both hepatocytes and hrP450, have been validated in-house previous to this work, and demonstrate low inter-day variability in terms of estimated CL int and fm CYP . Therefore, due to our confidence in the robustness of these assays, it was decided to generate only n = 3 for this study. For a few of the compounds, data had been generated before this study was performed. These data were included in the study and therefore n = 4 or n = 5 for these compounds (Tables 1 and 2) .
No systematic bias was observed to be associated with the compound position in the incubation plate or in the order of sample analysis on the LCMS instrument. Therefore, randomization of samples was deemed unnecessary.
Blinding of samples was not undertaken since prior knowledge of sample content was not expected to introduce any bias of the results. The procedure for compound incubation was performed according to a standardized methodology. Furthermore, LCMS analysis of samples and processing of data were controlled by the software used and interference by the experimentalist could be excluded.
Thawing of cryopreserved hepatocytes
A 10-donor pool of cryopreserved hepatocytes was used for all experiments. The pool consisted of five female and five male donors, age between 19 and 80 years. The pool was characterized with respect to drug metabolizing enzymes (specific P450 activities and general activities of conjugating enzymes), and activities are at average or above compared with individual donors available at the purchase. Cryopreserved cells were moved from À150°C freezer and immediately immersed in a pre-heated water bath kept at 37°C. When only a small ice crystal was left, the content was emptied into 50 mL hepatocyte suspension medium (HSM; William's medium E supplemented with 25 mM HEPES and 2 mM L-glutamine, adjusted to pH 7.4) and centrifuged for 6 min at 80× g at room temperature (RT). The medium was discarded, and cells were re-suspended in 50 mL Percoll solution and centrifuged at 100× g for 15 min at RT. The resulting pellet was resuspended in HSM; viability was determined by the trypan blue exclusion method, and cells were diluted to 2 ×10 6 cells . mL -1 in HSM. Minimum accepted viability was 75%.
CL int experiments in human hepatocytes
For the test compounds and inhibitors, 10 mM stock solutions were prepared in DMSO. In triplicate, 10 mM DMSO test compound solutions were diluted with 50% acetonitrile to a final concentration of 100 μM. In one of the triplicates, ketoconazole was added to a concentration of 300 μM; in one triplicate, quinidine was added to a concentration of 100 μM, and to the third triplicate, only DMSO was added. These solutions were further diluted with HSM giving a test compound concentration of 2 μM and ketoconazole and quinidine concentrations of 6 and 2 μM respectively. Hepatocyte suspension (25 μL) was added to each well in 96-well plates. Each plate represented a discrete incubation time point. The plates were pre-incubated for 10 min in an incubator at 37°C, 5% CO 2 , and reactions were started by addition of 25 μL of substrate/inhibitor solution to the cellcontaining wells. The final test compound concentration in the incubation was 1 μM, and ketoconazole and quinidine concentrations were 3 and 1 μM respectively. The solvent concentration in the incubations was 0.04% DMSO and 0.48% acetonitrile.
Following brief, gentle shaking, plates were placed back in the incubator. The reactions were stopped after 2, 15, 30, 45, 60, 75, 90, 120, 150 and 180 min by addition of three volumes (150 μL) of ice-cold stop solution (acetonitrile containing 0.8% formic acid and 5,5-diethyl-1,3-diphenyl-2-iminobarbituric acid as internal standard). Plates were centrifuged at 3200 × g at 4°C for 20 min. The supernatant (80 μL) was transferred to a new plate and diluted with an equal volume of water and was analysed for parent compound using LC-MSMS.
The analysis was performed on a Waters Quattro Ultima mass spectrometer with electrospray ionization (ESI) interface (Waters, Milford, MA, USA), an Agilent 1100 Series binary pump (Hewlett Packard GmbH, Waldbronn, Germany) configured with a CTC HTS PAL auto sampler (CTC Analytics AG, Zwingen, Germany). The analytical column used for chromatographic separation was an Atlantis T3 column (3 μm, 2.1 × 30 mm, Waters, Milford, MA, USA), and the mobile phases consisted of water (A) and acetonitrile (B) both containing 0.2% formic acid. The gradient used was 4% B for 0.1 min, followed by a linear increase to 95% B in 1.2 min at a flow rate of 0.7 mL·min À1 and a column temperature of 55°C. The injection volume was 5 μL. The samples were analysed with multiple reaction monitoring (MRM) in positive ionization mode. Data were acquired using MassLynx 4.1 acquisition software with Waters QuanLynx data processing.
Metabolite formation experiments in human hepatocytes
The test compound solutions were prepared according to the description for the CL int experiment with slight modification. The final test compound concentration was 4 μM, giving an intermediate test compound concentration of 400 μM. The organic solvent concentrations in the incubations were 0.07% DMSO and 0.47% acetonitrile. The experiments were performed in the same manner as the CL int experiments although only 0 and 240 min samples were taken, and samples were analysed using a high resolution QToF MS instrument for formation of metabolites.
Metabolite formation analysis was performed on an Acquity UPLC system interfaced with a Synapt G2 mass spectrometer (Waters, Milford, MA, USA). Chromatographic separation of metabolites and parent was carried out on an Acquity UPLC BEH C18 column (1.7 μm, 2.1 × 100 mm). The mobile phases consisted of 0.1% formic acid in water (A) and acetonitrile (B). The LC gradient was as follows: 0-6 min 10-70% B, 6-6.7 min 90% B at a flow rate of 0.5 mL·min À1 , and the column temperature was set to 45°C.
The Synapt G2 was operated under positive ESI conditions with a capillary voltage of 0.5 kV and cone voltage of 20 V. The data acquisition was performed using MS E with a mass Table 1 CL int in hrP450 and human hepatocytes and inhibition of metabolite formation data in human hepatocytes range of 80-1000 Da. For the low energy MS E acquisition, the trap and transfer energy were set to 4 and 3 V, respectively, while for the high energy MS E acquisition, the trap was ramped from 15 to 45 V and the transfer energy was held fixed at 12 V. Data were collected in centroid mode. Leucine-enkephaline was used as a lock mass (m/z 556.2771) for internal calibration at a concentration of 250 pmol·μL À1 and a flow rate of 40 μL·min À1 . MassLynx 4.1 (Waters, Milford, MA, USA) was used for the data acquisition.
CL int experiments in hrP450s
Each compound was incubated individually in nine P450 isoforms: CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4. Test compound solutions were prepared by adding 4 μL of 10 mM stock solution in DMSO to 196 μL of acetonitrile giving a concentration of 200 μM. The hrP450 enzymes were thawed on ice and then diluted in 0.1 M, pH 7.4 phosphate buffer. Test compound was added to the enzyme solution, and reaction mixtures were pre-incubated for 15 min at 37°C. Reactions were started by addition of NADPH (final concentration of 1 mM) and carried out at 37°C. Final concentrations of test compounds and CYP enzymes were 2 μM and 100 nM respectively. The final organic solvent concentrations in the incubations were 0.02% DMSO and 0.98% acetonitrile. After 0, 5, 10, 15 and 25 min aliquots were taken from the reaction mixture to a new plate and quenched with 120 μL of stop solution (acetonitrile containing internal standard). After quenching of the reaction, plates were centrifuged at 3200 × g for 20 min, placed at 4°C for 30 min, and then re-centrifuged at 3200 × g for 20 min to precipitate proteins. After the centrifugation, the supernatant was transfered to a new plate, diluted with an equal volume of water and analysed with LC-MSMS for the parent compound remaining.
The analysis was performed on a Waters XEVO TQD mass spectrometer (Waters, Milford, MA, USA) equipped with an Acquity I-class UPLC (Waters, Milford, MA, USA) configured with an Acquity Sample Management FTN auto sampler (Waters, Milford, MA, USA). The analytical column used for chromatographic separation was an Aquity UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm, Waters, Milford, MA, USA), and the mobile phases consisted of water (A) and acetonitrile (B) both containing 0.1% formic acid. The LC gradient was as follows: 0-0.2 min 5% B, 0.2-1.0 min 5-100% B, 1.0-1.4 min 100% B, 1.4-1.6 min 100-5% B, 1.6-2.0 min 5% B at a flow rate of 0.5 mL·min À1 and the column temperature was set to 40°C. The injection volume was 1 μL. The samples were analysed with MRM in positive or negative ionization mode. Data were acquired using MassLynx 4.1 acquisition software and data were processed with Waters QuanLynx Software.
Calculations of CL int values
For experiments with both hepatocytes and hrP450s, the slope value, k, was determined by linear regression of the natural logarithm of % parent remaining versus incubation time curve. The t ½ was determined from the slope value according to Equation 1.
The t ½ value is converted into the CL int using Equation 2a or 2b. CL int ; hepatocytes μL min -1 per million cells -1
Calculations of fm CYP values
From CL int values determined from hepatocytes, fm CYP2D6 and fm CYP3A were calculated according to Equation 3 and expressed as % reflecting the contribution of each enzyme to the overall hepatic metabolism of the compound of interest. These fm CYP values were used as entry parameters for in vitro to in vivo predictions of the DDI risk as well as to allow comparison across different in vitro systems.
For metabolite formation experiments, the area of all metabolites identified as compound related and the area of the parent compound was summarized with the aid of the ISEFs were estimated in-house for CYP3A4 and CYP2D6 (compounds in the study are predominantly metabolized by these isoforms to different extents) based on CL int estimated by substrate depletion of probe substrates in a pool of HLM (150 donors) as well as in hrP450s and median hepatic abundance of the respective P450 given by Simcyp (Table S1 ) according to the published procedure (Chen et al., 2011) (Equation 6). Midazolam and bufuralol were selected as probe substrates for CYP3A4 and CYP2D6 respectively and ISEFs for both CYPs were in agreement with ISEFs from Simcyp ( Table S1 ) that were used in the calculations.
ISEF ¼ CL int;HLM Abundance x CL int;hrCYP (6) In vitro to in vivo predictions DDI predictions and comparison between EM and PM were performed using two different methods: static (with fixed inhibitor concentrations at a steady state level) and dynamic (with inhibitor concentrations that vary over time). For both methods, the predicted output was expressed as fold AUC change to allow comparison with clinical data regardless of the absolute concentration of the drugs in circulation. AUCfold change is a parameter required by regulatory agencies as a measure of DDI extent or inter individual variability. For both approaches, the unbound hepatic inlet concentration of ketoconazole as inhibitor was used. The dynamic and physiologically based PK (PBPK) modelling were performed with the Simcyp software (version 16, Certara, Sheffield, UK). A subset of drugs (tolterodine, metoprolol, loratadine) and an AstraZeneca drug candidate (AZD1305) (Johnson et al., 2012) were selected for the PBPK modelling and all drug-specific parameters for these drugs are given in Table S2 . Physicochemical and in vitro data were generated for the compounds when literature data were not available. The fm CYP3A and fm CYP2D6 values estimated from human hepatocyte experiments were used for the simulations, and the retrograde method within the software was used to incorporate these values. The clearance values that were used as input can be found in Table S2 . The default healthy population (n = 100) was used as a starting point for the simulations and separated into two populations with 100% EM and PM respectively. The default gender (50% male and female) and age settings (20-50 years) were used for the simulations. In each run, n = 10 trials with n = 10 individuals were simulated. Minor changes were made to the default software compound files for tolterodine and metoprolol. Two separate compound files were used for tolterodine and metoprolol, respectively, using different clearance values for the EM and PM populations. For loratadine, a new model was built with a combination of a 'bottom-up' and 'top-down' methodology (Tsamandouras et al., 2015) , see Table S2 for input data. In order to get an estimate of clearance for loratadine, in vitro data were used (total hepatocyte CL int ) and scaled to a total clearance. The default software ketoconazole compound file was used for the 200 mg b.i.d. and the 400 mg once daily simulations. The model for AZD1305 has been published previously (Johansson et al., 2016) , and only minor changes were made to incorporate the fm CYP3A data. The equation used for the static modelling is shown below (Equation 7) (Obach, 2009 The values for fraction escaping gut metabolism (f g ) and fraction of total elimination due to hepatic metabolism (f m ) are given in Table S3 , and the fraction escaping gut metabolism in presence of inhibitor (f g,i ) was assumed to be 1 for all compounds when ketoconazole is used as inhibitor. The f gvalues were estimated according to Equation 8. Details are given in Table S3 .
f g Fraction escaping gut metabolism F Oral bioavailability f h Fraction escaping hepatic metabolism f a Fraction absorbed
The f h and f m -values were calculated according to Equations 9 and 10 respectively assuming the compounds are cleared mainly via hepatic metabolism in addition to renal clearance. Values for total clearance, renal clearance and fraction absorbed (f a ) were retrieved from the literature (Table  S3) , but no numbers for f a have been reported previously. For all the compounds studied, the f a was stated to be good and fast and was therefore assumed to be 0.95-1 for all compounds. This assumption was supported by the intrinsic Caco-2 cell apparent permeability values (Fredlund et al., 2017) . Hepatic blood flow set to 20 mL·min À1 ·kg
À1
For the predictions of the AUC-ratios in the presence and absence of ketoconazole, the unbound concentration of ketoconazole, I u , was calculated according to Equation 11 (Einolf, 2007) .
The dose, D, and dosing interval, Ƭ, of ketoconazole in the different interaction studies are given in Table S4 . The unbound inhibitor constant, K i,u , was set to 0.015 μM for ketoconazole. For the predictions of AUC increase in CYP2D6 PMs, 'dummy values' for I u (400 000) and K i,u (0.004) were used to achieve 100% inhibition of CYP2D6 to mimic the CYP2D6 PM phenotype. 
Data and statistical analysis
For CL int experiments, the quality of the data were judged by r 2 or standard error of the slope. If these were not accepted due to low metabolism (r 2 < 0.8 or P > 0.05 for t-test of standard error of the slope), the compounds were tested in the inhibition of metabolite experiments instead. All calculations were carried out by using Microsoft Excel and XLfit add-in version 5.2.2. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All experiments were performed according to validated procedures, and n = 3 was considered sufficient for each experiment. Positive controls were included to qualify each experiment. For some compounds, data already existed and therefore n > 3 for these.
Root mean square error (RMSE) and mean error (ME) of the predicted versus observed AUC-ratios were calculated according to Equations 12 and 13 respectively. RMSE describes precision and ME accuracy of the predicted AUC-ratios. High precision is reflected by a low RMSE value and high accuracy by an ME value close to zero.
N
Total number of observations in the analysis y i Predicted AUC-ratio x i
Observed AUC-ratio
Materials
Human cryopreserved hepatocytes were purchased from CelsisIVT (Baltimore, MD, USA 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
Estimation of fm CYP3A and fm CYP2D6 by hrP450 and human hepatocytes
Eight well described (Figure 1 ) and three AstraZeneca proprietary compounds, all of them CYP3A and/or CYP2D6 substrates metabolized by CYP3A and CYP2D6 to different extent were selected for this study. The fm CYP of these compounds were estimated in human hepatocytes incubated in the presence and absence of the selective CYP3A inhibitor ketoconazole or the selective CYP2D6 inhibitor quinidine (Li et al., 1999) (Table 2 ). For six of the selected compounds, CL int was determined by the well-established substrate depletion method (Table 1 ). The change in rate of elimination is depicted for the CYP3A substrate midazolam when co-incubated with ketoconazole (compared with midazolam alone) ( Figure S1A ) and for the CYP2D6 substrate bufuralol in the presence and absence of quinidine ( Figure S1B ). For five of the 11 compounds, the CL int values were below the limit of quantification. The fraction metabolized by CYP3A and CYP2D6 for these substances was determined instead by measuring the inhibition of metabolite formation following co-incubation with ketoconazole and quinidine respectively (Leandersson et al., poster presented (Table 2 ). The results from hrP450s clearly predicted a larger fraction metabolized by CYP3A and a smaller fraction by CYP2D6 as compared with the results obtained in human hepatocytes (Figures 2 and 3) . Metoprolol was an outlier showing a higher fm CYP3A when estimated in hepatocytes as compared with hrP450s and vice versa when calculating the fm CYP2D6 . For all compounds, except for bufuralol and metoprolol, fm CYP3A was predicted to be 80% or more of the total hepatic metabolism (less than 20% by CYP2D6). In contrast to hrP450s, human hepatocytes and selective inhibitors captured a wide range of estimated fm CYP3A (8-94%) and fm CYP2D6 (4-78%) suggesting a wider dynamic range of that method.
Prediction of clinical CYP3A victim DDI risk using a static equation
For six of the studied compounds (aripiprazole, AZD1305, loratadine, midazolam, tamsulosin and tolterodine), information on the interaction potential by ketoconazole in vivo in humans is available (Table 3 ). The change in AUC by ketoconazole was compared with the predicted change in AUC from the two in vitro models applying Equation 7 (see Methods for details). Overall, there was an excellent agreement between observed and predicted AUC-fold increases when using fm CYP3A values estimated in human hepatocytes. The predicted AUC-ratios were found to deviate less than twofold from what was observed in vivo, and there was no obvious systematic error in the predictions (RMSE = 0.98, ME = À0.4) ( Figure 4A , Table 3 ). Consequently, there was a strong correlation where r 2 of the regression line for predicted versus observed AUC-ratios was high (0.83). Utilization of fm CYP3A values estimated from hrP450 resulted in poor predictions where AUC-fold increases were considerably overpredicted (RMSE = 9.8, ME = 6.5, r 2 = 0.55) ( Figure 4B , Table 3 ).
Prediction of variation in compound exposure in CYP2D6 PM versus EM phenotypes using a static equation
The fm CYP2D6 values estimated by human hepatocytes were modelled using the static equation in order to predict the difference in AUC between CYP2D6 PM and EM for five compounds (aripiprazole, bufuralol, metoprolol, tamsulosin and tolterodine) metabolized by CYP2D6 to different extents. The predicted AUC-ratio in PM versus EM was in general somewhat underestimated but, except for tolterodine (2.9-fold underpredicted), in agreement (within twofold) with clinical observations (RMSE = 3.1, ME = À1.5). Also, there was a good correlation between the predicted versus observed AUC-ratios (r 2 = 0.82) ( Figure 5A , Table 3 ). When fm CYP2D6 values estimated by hrP450s were used, the AUC-ratio was predicted within twofold, except for tolterodine (8.3-fold underpredicted) and bufuralol (2.3-fold underpredicted). The overall precision was poor, and there was no correlation between predicted versus observed AUC-ratio (RMSE = 4.6, ME = À0.85, r 2 = 0.20) ( Figure 5B , Table 3 ). 
Figure 2
Correlation between the average fm CYP3A estimated in hrP450s versus human hepatocytes for 11 CYP3A and/or CYP2D6 substrates. The fm CYP3A was estimated in hepatocytes by comparing the metabolic turnover, following incubation of the compounds in the absence and presence of the selective CYP3A inhibitor ketoconazole. In hrP450s, CL int was estimated in 10 individual hrP450 isoforms and scaled up to an in vivo CL int by applying ISEFs and abundance for each individual P450 enzyme. The fm CYP3A was determined from the fraction of scaled in vivo CL int,CYP3A over Σscaled in vivo CL int,CYPi . Data represent mean values.
Prediction of clinical victim DDI risk using PBPK modelling and simulation
For the three compounds AZD1305, loratadine and tolterodine, fm CYP3A values estimated from human hepatocytes were assessed by PBPK modelling approach in order to predict the AUC-fold increase following oral co-administration with ketoconazole. The predicted AUC-ratios were similar to what was predicted by the static equation with a high degree of correlation between predicted and observed ratios ( Figure 6A , Table 3 ).
For the two CYP2D6 substrates metoprolol and tolterodine, fm CYP2D6 values estimated by human hepatocytes were modelled in order to predict the AUC-ratio between CYP2D6 PM and EM. The AUC-ratio for metoprolol was about threefold underpredicted by the PBPK model while twofold underpredicted by the static equation. For tolterodine, the AUC-ratio was well predicted by the PBPK model while threefold underpredicted by the static equation ( Figure 6B , Table 3 ).
Discussion
Two major goals in drug discovery and development programs are to ensure human safety and efficacy of candidate drugs. Therefore, it is of outmost importance to have an accurate prediction of variability in human exposure and potential DDI risks in patients. In this study, two alternative in vitro approaches, human hepatocytes combined with P450-selective inhibitors and hrP450s, were used to assess the risk of CYP3A victim DDI and differences in exposures between CYP2D6 EM and PM for a set of drugs with previously reported clinical victim DDI and PK profiles in humans. The compounds investigated (aripiprazole, bufuralol, loratadine, metoprolol, midazolam, tamsulosin, tolterodine, AZD1305 and three AstraZeneca proprietary compounds) are all metabolized by CYP3A and CYP2D6 to different extents. There is no significant non-P450 mediated metabolism reported for any of these compounds (Kamimura et al., 1998; Patki et al., 2003; Zhou et al., 2009) .
Using fm CYP values from human hepatocytes, modelled by a static equation, the prediction of AUC increase due to CYP3A victim DDI and the difference in AUC between CYP2D6 PM versus EM was within twofold of reported in vivo data except for one substance (tolterodine). We expect that utilizing the fm CYP data generated using human hepatocytes will allow us to distinguish between and to rank order drug candidates with respect to potential variations in exposure due to P450 victim DDIs and/or P450 polymorphism. This is of great value for drug design efforts in the drug discovery phase to identify and optimize compounds for a balanced metabolic profile, increasing the safety margins and decreasing the likelihood of adverse drug reactions ultimately leading to development of safer drugs for patients.
In human hepatocytes, the metabolic turnover of the well-known CYP2D6 substrate bufuralol was, as expected, found to be inhibited significantly by quinidine. Bufuralol was also inhibited to some extent by ketoconazole (Table 1) suggesting metabolism by CYP3A, which to our knowledge, has not been reported previously. Instead, in addition to CYP2D6, bufuralol has been reported to be metabolized to some extent by CYP1A2 and CYP2C9 (Rendic and Di Carlo, 1997) . Bufuralol has also been reported to be conjugated by glucuronic acid (Francis et al., 1982) , which may partly explain the inhibition of its metabolism since certain UDP glucuronosyltranferases are known to be inhibited by ketoconazole (Yong et al., 2005) . It was confirmed in our study that glucuronidation of bufuralol is a minor pathway of the metabolism of bufuralol which was partly inhibited by ketoconazole (data not shown).
Prediction of DDI potential and differences in PK profiles in CYP2D6 PM versus EM was less accurate when using fm CYP values estimated in hrP450s compared with human hepatocytes. A potential caveat with the approach using hrP450s and scaling factors was recently demonstrated (Siu and Lai, 2017) . Depending on the substrates selected for estimation of scaling factors, the fm CYP values could vary significantly. This was exemplified by losartan where fm CYP3A4 was predicted between 12-25% (using testosterone as CYP3A substrate) and 78-91% (using midazolam or nifedipine as CYP3A substrates). In a study by Chen and colleagues (2011) , the accuracy of fm CYP predicted by hrP450 was demonstrated to be in acceptable agreement with the observed fm CYP using HLM and inhibitors. One outlier in this study was the only CYP3A and CYP2D6 mixed substrate for which a more than 10-fold discrepancy was observed between fm CYP2D6 when estimated by the two separate in vitro methods. This demonstrates the unsuitability of hrP450 approach for this mixed CYP3A/CYP2D6-substrate, which is well in line with our findings for the substrates in the present study, selected for their mixed CYP3A/2D6 properties. One 
Figure 3
Correlation between the average fm CYP2D6 estimated in hrP450s versus human cryopreserved hepatocytes for eight CYP2D6 and/or CYP3A substrates. The fm CYP2D6 was estimated in hepatocytes by comparing metabolic turnover in absence and presence of the selective CYP2D6 inhibitor quinidine. In hrP450s, CL int was estimated in 10 individual hrP450 isoforms and scaled up to an in vivo CL int by applying ISEFs and abundance for each individual P450 enzyme. The fm CYP2D6 was determined from the fraction of scaled in vivo CL int,CYP2D6 over Σscaled in vivo CL int,CYPi . Data represent mean values.
explanation for the issue related to studying individual P450s in isolation is the complexity of P450 function described in a recent review, such as interactions with redox partners, allosteric mediators and also with other P450 isoforms that will affect the P450 activity (Kandel and Lampe, 2014) . Disrupting any of these interactions might lead to altered metabolic pathways. By using hepatocytes, a more complete 'in vivo-like' in vitro system compared with hrP450s, the risk of incorrect estimation of fm CYP is alleviated. In addition, hepatocytes represent a more complete in vitro system with regard to drug metabolizing enzymes expressing non-P450 phase I as well as phase II enzymes. Ignoring these additional metabolic pathways could lead to erroneous prediction of victim DDIs. The concept behind the static equation (details given in Methods) applied for assessment of AUC-ratios due to CYP3A victim DDI and CYP2D6 polymorphism is well established, originally described by Rowland and Matin (1973) . The approach with a static equation has proved to be simple to use and give accurate predictions. One key input parameter in the equation is the inhibitor concentration. The most relevant inhibitor concentration to be used in the equation has been debated in the literature. It has been shown that the use of hepatic inlet concentration is preferred rather than systemic plasma concentrations for prediction of reversible DDI (Ito et al., 2004; Obach, 2009 ). Therefore, predicted free hepatic inlet concentration was applied as the inhibitor concentration in our study.
Advanced PBPK based models that integrate systemspecific components as P450 abundance, differences within a population and drug specific components such as CL int , fraction unbound in plasma and physicochemical properties can be built using commercial software (Rostami-Hodjegan and Tucker, 2007) . Several studies have shown the usefulness of PBPK modelling in predicting CYP3A DDI risk as well as capturing AUC variability for drugs that are predominantly metabolized by CYP2D6 (Vieira et al., 2014; Yoshida et al., 2016) . In this work, we demonstrated the usefulness of accurately determined fm CYP data for the build-up of PBPK models. Simulations applying the compound file can then be used to assess DDI risk and variability within a population. These compound files are aimed for model continuum and to continuously be developed as more data become available for a drug candidate. CYP3A victim DDI risks as well as AUC-ratio of CYP2D6 PM over EM, simulated by PBPK modeling, were well predicted for the selected compounds and very close to the predictions using static equations.
In conclusion, in vitro as well as in silico tools with a rapid turn-around time and high accuracy in prediction of variability in drug exposure in patients are essential for risk assessment of NCE in the discovery phase to aid drug design and optimization of this potential liability. We suggest a static Vieira et al. (2014) . b Hendset et al. (2007) . c Johansson et al. (2016) . d Dayer et al. (1985) . e Chaikin et al. (2005) . f Kosoglou et al. (2000) . g Lennard et al. (1982) . h Chung et al. (2006) . i Chen et al. (2006) . j Troost et al. (2011) . k Choi et al. (2012) . l Brynne et al. (1999) . m Malhotra et al. (2011) . n AUC-ratio presented as geometric mean ratio and 90% CI. o Simulated with the study design of Chaikin et al., 2005. equation should be applied to model fm CYP values estimated in human hepatocytes combined with P450-selective inhibitors to assess the risk of variable exposures due to victim DDI and enzyme polymorphism in drug discovery. In our study, the concept was successfully demonstrated for the two major P450s, CYP3A and CYP2D6, but is also expected to result in reliable predictions for other P450s (or in principle for other drug metabolizing enzymes as well) provided that selective and potent inhibitors can be identified. The static equation is easy to use, and less input parameters are required compared with a dynamic PBPK model. Therefore, a static model is considered sufficient in the drug discovery phase, and the use of dynamic PBPK modelling should be used as a complementary tool for more developed compounds in late 
Figure 4
Correlation between predicted and observed AUC-fold increase in humans following oral co-administration of the selective CYP3A inhibitor ketoconazole. Line of unity (solid), twofold deviation (dashed line), regression line (dotted). The fm CYP3A values estimated in human hepatocytes (A) and hrP450s (B) were applied for the predictions using a static equation.
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Figure 5
Correlation between the predicted and the observed AUC-fold increase in CYP2D6 poor metabolizers compared with extensive metabolizers. Line of unity (solid), twofold deviation (dashed line), regression line (dotted). The fm CYP2D6 values estimated in human hepatocytes (A) and hrP450s (B) were applied for the predictions using a static equation.
discovery phase and for clinical candidates to support and potentially refine the predictions by the static model and maintain modelling continuum. We believe that the approach described will enhance the likelihood of selecting a candidate drug for clinical development with reduced risk of adverse drug reactions and/or lack of efficacy due to large variations in drug exposure.
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Figure 6
Correlation between predicted and observed AUC-fold increase in humans for AZD1305 (AZ1), loratadine (LOR) and tolterodine (TOL) following oral co-administration of the selective CYP3A inhibitor ketoconazole (A). Correlation between predicted and observed AUC-fold increase in CYP2D6 PMs compared with EMs for metoprolol (MET) and tolterodine (6). Line of unity (solid), twofold deviation (dashed line). The fm CYP3A and fm CYP2D6 values respectively estimated in human hepatocytes were applied for the predictions using a static equation (triangles) and Simcyp (squares).
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https://doi.org/10.1111/bph.14203 Figure S1 Metabolic turnover of midazolam (1A) and bufuralol (1B) in human 59 hepatocytes when incubated in absence (circles) and presence (triangles) of selective 60 CYP3A (ketoconazole) and CYP2D6 (quinidine) inhibitors respectively.
